{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:10:25Z","timestamp":1791227425466,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Roche S.p.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18662-y","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:06:05Z","timestamp":1759752365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Marco","family":"Sposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Belluomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Nocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Insolda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Mariangela","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Simbolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lugini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Buzzacchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Verderame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spinnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Calvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Jos\u00e9","family":"Soto Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Pradelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Sicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"18662_CR1","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 93, 102693 (2024).","journal-title":"Cancer Epidemiol."},{"issue":"10","key":"18662_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo, C. et al. Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer. J. Thorac. Oncol. 16(10), 1647\u20131662 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"18662_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO precision medicine working group. Ann. Oncol. 35(7), 588\u2013606 (2024).","journal-title":"Ann. Oncol."},{"issue":"4","key":"18662_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34(4), 339\u2013357 (2023).","journal-title":"Ann. Oncol."},{"issue":"8","key":"18662_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5(8), 860\u2013877 (2015).","journal-title":"Cancer Discov."},{"key":"18662_CR6","doi-asserted-by":"publisher","first-page":"1436588","DOI":"10.3389\/fonc.2024.1436588","volume":"14","author":"M Sposito","year":"2024","unstructured":"Sposito, M. et al. Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study. Front Oncol. 14, 1436588 (2024).","journal-title":"Front Oncol."},{"issue":"3","key":"18662_CR7","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury, C. A. et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE 17(3), e0264138 (2022).","journal-title":"PLoS ONE"},{"issue":"9","key":"18662_CR8","doi-asserted-by":"publisher","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15(9), e0237802 (2020).","journal-title":"PLoS ONE"},{"issue":"5","key":"18662_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","volume":"20","author":"TA Clark","year":"2018","unstructured":"Clark, T. A. et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J Mol Diagn. 20(5), 686\u2013702 (2018).","journal-title":"J Mol Diagn."},{"key":"18662_CR10","unstructured":"SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED). FoundationOne\u00aeCDx., (2024). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019S054B.pdf February 1, 2024."},{"key":"18662_CR11","unstructured":"SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED). FoundationOne\u00aeLiquid CDx., (2024). https:\/\/www.foundationmedicine.com\/sites\/default\/files\/media\/documents\/2025-04\/v16_RAL-0035_P190032_S024_F1LCDx_Technical_Clean%20Label_10DEC2024.pdf February 1, 2024."},{"issue":"8038","key":"18662_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis, F. et al. CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038), 462\u2013471 (2024).","journal-title":"Nature"},{"issue":"2","key":"18662_CR13","doi-asserted-by":"publisher","first-page":"e000706","DOI":"10.1136\/esmoopen-2020-000706","volume":"5","author":"S Papillon-Cavanagh","year":"2020","unstructured":"Papillon-Cavanagh, S. et al. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 5(2), e000706 (2020).","journal-title":"ESMO Open."},{"issue":"16","key":"18662_CR14","doi-asserted-by":"publisher","first-page":"TPS8655","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8655","volume":"42","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis, F. et al. TRITON: Phase 3b study of tremelimumab (T)+ durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and\/or KEAP1 and\/or KRAS mutations. J. Clin. Oncol. 42(16), TPS8655\u2013TPS9655 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"18662_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12885-023-10778-6","volume":"23","author":"C Julian","year":"2023","unstructured":"Julian, C. et al. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and\/or KEAP1 mutations in a real-world setting. BMC Cancer 23(1), 352 (2023).","journal-title":"BMC Cancer"},{"issue":"9","key":"18662_CR16","doi-asserted-by":"publisher","first-page":"e0238358","DOI":"10.1371\/journal.pone.0238358","volume":"15","author":"NJ Shire","year":"2020","unstructured":"Shire, N. J. et al. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PLoS ONE 15(9), e0238358 (2020).","journal-title":"PLoS ONE"},{"issue":"3","key":"18662_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J. Thorac. Oncol. 17(3), 399\u2013410 (2022).","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"18662_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","volume":"18","author":"JV Alessi","year":"2023","unstructured":"Alessi, J. V. et al. Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC. J Thorac. Oncol. 18(6), 731\u2013743 (2023).","journal-title":"J Thorac. Oncol."},{"issue":"2","key":"18662_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","volume":"24","author":"KC Arbour","year":"2018","unstructured":"Arbour, K. C. et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin. Cancer Res. 24(2), 334\u2013340 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"18662_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4143\/crt.2024.046","volume":"57","author":"S Choi","year":"2025","unstructured":"Choi, S. et al. Association of TP53 mutation status and sex with clinical outcome in non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective cohort study. Cancer Res. Treat. 57(1), 70\u201382 (2025).","journal-title":"Cancer Res. Treat."},{"key":"18662_CR21","doi-asserted-by":"publisher","first-page":"108452","DOI":"10.1016\/j.lungcan.2025.108452","volume":"204","author":"J Feng","year":"2025","unstructured":"Feng, J. et al. Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations. Lung Cancer 204, 108452 (2025).","journal-title":"Lung Cancer"},{"issue":"1","key":"18662_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin, K. et al. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: A meta-analysis. BMC Cancer 20(1), 328 (2020).","journal-title":"BMC Cancer"},{"key":"18662_CR23","doi-asserted-by":"publisher","first-page":"103929","DOI":"10.1016\/j.critrevonc.2023.103929","volume":"184","author":"MG Ferrara","year":"2023","unstructured":"Ferrara, M. G. et al. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. Crit. Rev. Oncol. Hematol. 184, 103929 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"18662_CR24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1007\/s12094-023-03362-8","volume":"26","author":"M Provencio-Pulla","year":"2024","unstructured":"Provencio-Pulla, M. et al. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. Clin. Transl. Oncol. 26(6), 1384\u20131394 (2024).","journal-title":"Clin. Transl. Oncol."},{"key":"18662_CR25","doi-asserted-by":"publisher","first-page":"695770","DOI":"10.3389\/fonc.2021.695770","volume":"11","author":"M Grard","year":"2021","unstructured":"Grard, M. et al. Homozygous co-deletion of type I interferons and CDKN2A genes in thoracic cancers: Potential consequences for therapy. Front Oncol. 11, 695770 (2021).","journal-title":"Front Oncol."},{"issue":"8","key":"18662_CR26","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1878-0261.13206","volume":"16","author":"Y Peng","year":"2022","unstructured":"Peng, Y. et al. Co-occurrence of CDKN2A\/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma. Mol. Oncol. 16(8), 1746\u20131760 (2022).","journal-title":"Mol. Oncol."},{"issue":"15","key":"18662_CR27","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.3390\/cancers13153809","volume":"13","author":"M Franchi","year":"2021","unstructured":"Franchi, M., Cortinovis, D. & Corrao, G. Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: A real-world evaluation in Italy. Cancers (basel). 13(15), 3809 (2021).","journal-title":"Cancers (basel)."},{"issue":"6","key":"18662_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1158\/1055-9965.EPI-21-0876","volume":"31","author":"D Backenroth","year":"2022","unstructured":"Backenroth, D. et al. Accounting for delayed entry in analyses of overall survival in clinico-genomic databases. Cancer Epidemiol. Biomarkers Prev. 31(6), 1195\u20131201 (2022).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"18662_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jtho.2023.11.009","volume":"19","author":"X Le","year":"2024","unstructured":"Le, X. Partners in crime: Co-occurring genetic alterations in EGFR-mutant NSCLC. J. Thorac. Oncol. 19(2), 190\u2013192 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"18662_CR30","first-page":"614","volume":"16","author":"F Passiglia","year":"2024","unstructured":"Passiglia, F. et al. Actionable NSCLC mutation identification by comprehensive genomic profiling for clinical trial enrollment: The European program for the routine testing of patients with advanced lung cancer (EPROPA). J. Thorac. Oncol. 16, 614\u2013624 (2024).","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"18662_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","volume":"19","author":"P Stockhammer","year":"2024","unstructured":"Stockhammer, P. et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J. Thorac. Oncol. 19(2), 240\u2013251 (2024).","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"18662_CR32","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.1016\/j.jtho.2024.09.703","volume":"19","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis, F. et al. P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and\/or KRAS mutations. J. Thorac. Oncol. 19(10), S389 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"18662_CR33","unstructured":"Novello S, Troncone U, Malapelle U. ATLAS, Biomarkers atlas https:\/\/biomarkersatlas.com. September 13, 2024."},{"key":"18662_CR34","doi-asserted-by":"publisher","first-page":"107787","DOI":"10.1016\/j.lungcan.2024.107787","volume":"191","author":"U Malapelle","year":"2024","unstructured":"Malapelle, U. et al. The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database. Lung Cancer 191, 107787 (2024).","journal-title":"Lung Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18662-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:07:26Z","timestamp":1760141246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18662-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18662"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18662-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of clinical research of AOUI Verona (protocol code 59115 of 11\/10\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"34807"}}